ContraFect Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CFRXQ research report →
Companywww.contrafect.com
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
- IPO
- 2014
- Employees
- 23
- HQ
- Yonkers, NY, US
Price Chart
Valuation
- Market Cap
- $107
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -347.26%
- ROIC
- -4817.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-65,153,000 · -221.24%
- EPS
- $-124.97 · -183.25%
- Op Income
- $-56,889,000
- FCF YoY
- -11.94%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -9.21
- Avg Volume
- 8.54K
Get TickerSpark's AI analysis on CFRXQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CFRXQ Coverage
We haven't published any research on CFRXQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CFRXQ Report →